Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Old API Wind-down Ltd - Ordinary Shares ARLZQ

Healthcare Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently... see more

Bullboard (OTCPK:ARLZQ)

View:
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
Comment by GoldenDilemmaon Apr 11, 2017 8:14am

RE:RE:RE:RE:RE:RE:Bloom Burton upgrade to Buy; Share Price up 11% on Volume

What a breath of fresh air it is to be liquid from ARLZ. To any of the ARZ/ARLZ longs on here who are touting the future fantasies: I am on the sidelines watching ARLZ with liquid money that can ...more  
104
Discussion
Comment by 2quick154on Apr 10, 2017 8:58pm

RE:RE:RE:RE:RE:Bloom Burton upgrade to Buy; Share Price up 11% on Volume

Wow.  What's the point of being invested in this company anymore?  The whole thesis was yosprala... and how much money was spent on that? What a failure... everything is based on ...more  
98
Discussion
Comment by biggerron Apr 10, 2017 6:04pm

RE:RE:RE:RE:Bloom Burton upgrade to Buy; Share Price up 11% on Volume

Zontivity is already known to doctors because it was marketed by Merck earlier so there won't be a need for too many salespeople. Merck did most of the advertising job for Zontivity when it first ...more  
84
Discussion
Comment by biggerron Apr 10, 2017 5:59pm

RE:RE:RE:RE:Bloom Burton upgrade to Buy; Share Price up 11% on Volume

but there are also lots of  patients with that problem, millions over the age of 50 have some sort of a heart problem
57
Discussion
Comment by CHECKMATE77on Apr 10, 2017 4:39pm

RE:RE:RE:Bloom Burton upgrade to Buy; Share Price up 11% on Volume

Already a bunch of anti- coagulants on the market another from a company without deep pockets and a dedicated sales force is toast
107
Discussion
Comment by biggerron Apr 10, 2017 4:35pm

RE:RE:Bloom Burton upgrade to Buy; Share Price up 11% on Volume

there is a place for Zontivity because it works on a different path from Warfarin and they both cause bleeding so it's a draw. ARZ can always drop the price a bit on Zon to make it more ...more  
98
Discussion
Comment by kuatoliveson Apr 10, 2017 4:03pm

RE:Bloom Burton upgrade to Buy; Share Price up 11% on Volume

What's more likely? That a management team that has been wrong about everything up until this point is right about zontivity? OR They're still wrong? My bet is on the latter.
77
Discussion
Post by snootchybootchyon Apr 10, 2017 1:23pm

Bloom Burton upgrade to Buy; Share Price up 11% on Volume

The copy of the Bloom Burton report can be found here.  Bloom Burton is conservatively forecasting $363 million (USD)  in peak sales for Zontivity (with potential upside peak sales of ...more  
221
Discussion
Comment by kuatoliveson Apr 07, 2017 3:47pm

RE:RE:Waikt .... What?

You also can't relaunch a product that already failed once and expect much success. Could be wrong, but, I doubt it.
86
Discussion
Comment by biggerron Apr 07, 2017 2:56pm

RE:Waikt .... What?

speaking of new blood, the launch of Zontivity this month could be a good stimulant for the SP, lots of folks have blood clots. I knew that the other drug would be a failure, you can't combine two ...more  
121
Discussion
Comment by GoldenDilemmaon Apr 07, 2017 10:46am

RE:RE:RE:Waikt .... What?

Any changes to management, count it as another kiss of death BTW...
88
Discussion
Comment by WCoyoteon Apr 07, 2017 10:12am

RE:RE:Waikt .... What?

I know that, however it at the very least sends a message. BTW, the larger investors cannot be happy either.
93
Discussion
Comment by GoldenDilemmaon Apr 07, 2017 10:09am

RE:Waikt .... What?

You are a small fish in the game. Retail don't make up this float. 
92
Discussion
Post by WCoyoteon Apr 07, 2017 10:02am

Waikt .... What?

The list of BOD members to be voted for is:  Adrian Adams, Jason Aryeh, Neal Fowler, Rob Harris, Arthur Kirsch, Ken Lee, Seth Rudnick and Martin Thrasher.   What exactly is going on over ...more  
242
Discussion
Comment by GoldenDilemmaon Apr 07, 2017 7:41am

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:FYI

Let's revisit this post and these words of yours after a disappointing Q1 readout. If you think emotional selling is what has bled this company out over 12+ months, think again.
99
Discussion
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities